Salivary Gland Therapy Shows Promising Clinical Outcomes in Actuate Therapeutics Phase II Trial

FUD_Whisperer · 2025-12-26T04:36:48+00:00

Actuate Therapeutics reported positive Phase II trial results for elraglusib with carboplatin and cisplatin in treating advanced salivary gland cancers, showing significant survival improvements and strong market response.

FUD_Whisperer

2025-12-26 04:36:48

Abstract generation in progress

Actuate Therapeutics, Inc. (ACTU) unveiled encouraging clinical outcomes from its Phase II investigation into elraglusib combined with standard chemotherapy agents carboplatin and cisplatin for treating advanced metastatic salivary gland malignancies. The trial, which examined both adenoid cystic carcinoma (ACC) and non-ACC subtypes, enrolled a balanced patient population of 47% ACC cases and 53% non-ACC cases.

Survival Data Demonstrates Clinical Benefit

The study demonstrated substantial survival improvements across the patient cohort. Overall median survival reached 18.6 months, with 58% of patients remaining alive at the one-year mark and 40% maintaining survival through the two-year period. The non-ACC patient subset showed particularly strong results, achieving a median overall survival of 27.8 months—a notable advancement for this treatment-resistant patient population.

Progression-free survival metrics revealed a median PFS of 6.4 months, with 27% of participants remaining without disease progression at one year. This performance compared favorably against historical benchmarks, which showed typical PFS of less than 6 months for non-ACC salivary gland disease and significantly longer but more variable courses for ACC patients.

Market and Research Recognition

The promising data have been formally published in Clinical Cancer Research, establishing peer-reviewed validation for the therapeutic approach. Market participants responded positively to the announcement, with Actuate shares gaining over 4% in pre-market trading Monday, building on Friday’s close of $7.52, which reflected a 1.35% session gain.

The trial results underscore the potential of this elraglusib-based combination strategy for advanced salivary gland cancer patients who have limited therapeutic options, representing a meaningful step forward in addressing this challenging oncology indication.

This report reflects the clinical findings and market activity related to Actuate Therapeutics’ trial announcement.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.